Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent

Ian T Meredith, Stefan Verheye, Christophe L Dubois, Jean Fajadet, Didier Carrie, Simon Walsh, Keith G Oldroyd, Olivier Varenne, Seif El-Jack, Raul Moreno, Anita A Joshi, Dominic J Allocco, Keith D Dawkins

Research output: Contribution to journalArticleResearchpeer-review

167 Citations (Scopus)


OBJECTIVES: This study sought to compare the safety and efficacy of 2 dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) (Boston Scientific Corp., Natick, Massachusetts) compared with the durable polymer PROMUS Element EES (Boston Scientific Corp.). BACKGROUND: Durable polymer coatings on drug-eluting stents have been associated with chronic inflammation and impaired healing. Bioabsorbable polymer-coated drug-delivery systems may reduce the risk of late adverse events, including stent thrombosis, and thus the need for prolonged dual-antiplatelet therapy. METHODS: A total of 291 patients with a de novo lesion /=2.25 to
Original languageEnglish
Pages (from-to)1362 - 1370
Number of pages9
JournalJournal of the American College of Cardiology
Issue number15
Publication statusPublished - 2012

Cite this